Evidence map›Paper›PMID 36171549›Full record

ArticleBMC infectious diseases2022

Pneumococcal vaccination coverage in individuals (16-59 years) with a newly diagnosed risk condition in Germany.

Arijita Deb, Bélène Podmore, Rosemarie Barnett, Dominik Beier, Wolfgang Galetzka, Nawab Qizilbash, Dennis Haeckl, Timo Boellinger, Kelly D Johnson, Thomas Weiss

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Arijita DebMerck & Co., Inc, Kenilworth, NJ, USA.
Bélène PodmoreOXON Epidemiology, London, UK.
Rosemarie BarnettOXON Epidemiology, London, UK.
Dominik BeierInGef-Institute for Applied Health Research Berlin GmbH, Berlin, Germany.
Wolfgang GaletzkaInGef-Institute for Applied Health Research Berlin GmbH, Berlin, Germany.
Nawab QizilbashOXON Epidemiology, London, UK.
Dennis HaecklWIG2 GmbH, Leipzig, Germany.
Timo BoellingerMSD Sharp & Dohme GmbH, Haar, Germany.
Kelly D JohnsonMerck & Co., Inc, Kenilworth, NJ, USA. kelly.johnson@merck.com.
Thomas WeissMerck & Co., Inc, Kenilworth, NJ, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USInstitute for Applied Economic Research · DEMRC Epidemiology Unit · GBLondon School of Hygiene & Tropical Medicine · GBMSD (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and timing among individuals aged 16-59 years in Germany who were recommended to receive pneumococcal vaccination, according to STIKO.

methodsA retrospective cohort analysis was conducted using the German InGef database. Individuals aged 16 to 59 years diagnosed with at least one "at-risk" (chronic disease) or "high-risk" (e.g., immunocompromising) condition considered to be at-risk of pneumococcal infection were identified at the time of first diagnosis, between January 1, 2016 and December 31, 2018, and followed up until December 31, 2019. The percentage of cumulative pneumococcal VCR with 95% confidence interval (CI) was reported for each calendar year of follow-up.

resultsThere were 334,292 individuals followed for a median of 2.38 (interquartile range (IQR) 1.63-3.13) person years. For individuals aged 16-59 years diagnosed with an incident risk condition in 2016, pneumococcal VCR increased from 0.44% (95% CI 0.41-0.48) in 2016 to 1.24% (95% CI 1.18-1.30) in 2019. In 2019, VCRs were higher in individuals with high-risk conditions compared with at-risk conditions (2.24% (95% CI 2.09-2.40) vs. 0.90% (95% CI 0.85-0.96)). In 2019, VCRs were higher in individuals aged 50 to 59 years compared with individuals aged 16 to 49 years (2.25% (95% CI 2.10-2.41) vs. 0.90% (95% CI 0.84-0.96)). Similar trends were observed in individuals with newly diagnosed risk conditions identified in 2017 and in 2018. Older age, influenza vaccination and increasing number of risk conditions increased the likelihood of pneumococcal vaccination. Median time to vaccination from diagnosis of the risk condition was shorter for high-risk conditions (369.5 days (IQR 155.8-702.0)) compared to at-risk conditions (435.5 days (IQR 196.3-758.8)).

conclusionDespite recommendations from STIKO, pneumococcal vaccination coverage remains very low and with long delays in vulnerable individuals aged 16-59 in Germany. Further efforts are required to increase immunization levels and shorten time to vaccination among individuals 16-59 years of age developing conditions with higher susceptibility to pneumococcal infection.

Indexed as

Pneumococcal InfectionsVaccination CoverageAdolescentAdultHumansMiddle AgedPneumococcal VaccinesRetrospective StudiesStreptococcus pneumoniaeVaccinationYoung AdultPneumococcal VaccinesClaims dataGermanyPCV13Pneumococcal conjugate vaccinePneumococcal diseasePneumococcal vaccinationPPSV23Vaccine coverage rate

Identifiers

PMID36171549
PMCPMC9517976
OpenAlexW4297473695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.